IL17A and systemic sclerosis: The addition of 1,25(OH)2D3 in PBMCs significantly reduced the production and the mRNA expression of IL-17A, in a dose-dependent way in SSc subjects (10-9M: 394.99±126.64, p<0.05; 10-8M: 345.44±125.48, p<0.05; 10-7M 322.62±123.06, p<0.01 vs 464.54 pg/ml in untreated cells) and in healthy subjects (10-9M: 140.54±50.66, n.s.; 10-8M 72.55±39.04, p <0,0001; 10-7M 45.06±19.5, p<0.0001 vs 150.85±57.38 pg/ml in untreated cells) (Figure 1).